NDAINHALATIONAEROSOL, METERED4 Generics Approved
Approved
Nov 2004
Lifecycle
Peak
Competitive Pressure
38/100
Clinical Trials
8
Data completeness
5/8 — Partial
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATROVENT HFA is an inhaled anticholinergic bronchodilator containing ipratropium bromide, delivered via metered-dose aerosol. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma by blocking acetylcholine receptors in airway smooth muscle to reduce bronchoconstriction. The HFA formulation replaced older CFC propellants, improving environmental safety while maintaining clinical efficacy.
$132MPart D
PeakStable
3.3 years to LOEProduct is at peak maturity with $132M in Part D spending; teams are focused on defending market share against generics and newer agents rather than driving growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Ipratropium Bromide in Peri-Operative COPD
Started Oct 2013
192 enrolled
Pulmonary Disease, Chronic Obstructive
Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
Started Jun 2008
6 enrolled
COPD
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
Started Oct 2002
1,118 enrolled
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
Started Oct 2000
41 enrolled
Pulmonary Disease, Chronic Obstructive
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Started Oct 2000
30 enrolled
Pulmonary Disease, Chronic Obstructive
Worked on ATROVENT HFA at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.